Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Weekly Topotecan With Cisplatin in Advanced Stage or Recurrent Cervical Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have persistent, recurrent, or primary Stage IVB carcinoma of the cervix not amenable to curative therapy with either surgery and/or radiation.~* Patients must have biopsy proven squamous cell, adenosquamous, or adenocarcinoma histology.~* Patients do not require measurable disease.~* Patients must have adequate organ function defined by laboratory work.~* Patients must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.~* Patients must have recovered from any effects attributable to surgery, radiation, or chemoradiotherapy. A minimum of six weeks shall have passed since the last administration of chemoradiotherapy or three weeks for radiation therapy alone.~* Patients must be free of clinically significant infections.~* Patients must be age 19 or greater and have signed informed consent.~Exclusion Criteria:~* Patients who are pregnant or lactating.~* Patients with history of other malignancies (except non-melanoma skin cancer) within the last 5 years are ineligible.~* Patients with non-squamous, adenosquamous, or adenocarcinoma histology.~* Patients with bilateral hydronephrosis that cannot be alleviated by ureteral stents or percutaneous drainage.~* Patients currently receiving any or having received other investigational agents within the last 30 days are ineligible.~* Patients with known hypersensitivity to topotecan or cisplatin.~* Patients with craniospinal metastases.~* Patients with uncontrolled current illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, serious peripheral neuropathy, or psychiatric illness/social situations that would limit or preclude compliance with study requirements are ineligible.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).